|  | Cancer | Lung Cancer

Carbo Taxol Treatment for Lung Cancer

Lung cancer is a deadly disease. Only 15 percent of lung cancer patients survive more than five years after diagnosis, according to Surveillance, Epidemiology and End Results. Carbo-Taxol is a combination chemotherapy for lung cancer, based on carboplatin and paclitaxel.

  1. Effects

    • Carbo-Taxol has been shown to have positive effects on survival of lung cancer patients, according to LungCancerOnline.org. Carbo-Taxol performs similarly to other combination therapies for lung cancer, such as cisplatin/gemicitabine and cisplatin/paclitaxel, according to "Clinical Oncology."

    Benefits

    • Side effects of Carbo-Taxol are less severe than other chemotherapy regimens for lung cancer, according to "Clinical Oncology."

    Identification

    • Carboplatin belongs to a group of chemotherapy drugs called alkylating agents.
      Taxol belongs to a group of chemotherapy drugs called antimicrotubular agents.

    Expert Insight

    • Avastin (bevacizumab) when combined with Carbo-Taxol performs much better than Carbo-Taxol alone, according to a 2006 study published in "New England Medical Journal."

    Side Effects

    • Carbo-Taxol has many side effects including hair loss, fatigue, low white blood cell count, nausea, increased risk of blood clots, damage to the veins, sore eyes, diarrhea and constipation, according to Cancernet.co.uk.

Lung Cancer - Related Articles